Pharmacotherapy for Patients with Personality Disorders
There is an increasing interest in the pharmacological treatment of personality disorders. Despite the experience that psychotropic drugs often have only a modest effect on patients with personality disorders, medication has been suggested as an important adjunct to the overall treatment of these patients (Gitlin, 1993; Soloff, 1994). According to various conceptualisations of personality pathology, one may apply different strategies in the pharmacological treatment of personality disordered patients (Gitlin, 1993). Treatment may be directed towards various personality disorder categories, or specific symptom clusters within or across disorders, some of which have been suggested to have a biological substrate (Tuinier and Verhoeven, 1995; Soloff, 1994). The symptom clusters most frequently cited are affective instability, impulsivity, and aggressiveness, anxiety, and inhibition, and cognition and perception (DeBattista and Glick, 1995). A third alternative is to treat associated axis I disorders. However, in the presence of personality pathology the response to pharmacological treatment of axis I disorders is less pronounced (Reich and Vasile, 1993; Shea, Widiger, and Klein, 1992).
KeywordsBorderline Personality Disorder Eating Disorder Mood Disorder Personality Disorder Social Phobia
Unable to display preview. Download preview PDF.
- American Psychiatric Association, 1994, Global assessment of functioning scale (GAF Scale). Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Washington D.C.Google Scholar
- Derogatis, L.R., 1977, The SCL-90: administration, scoring, and procedures manual-II for the revised version, Clinical Psychometric Research, Baltimore.Google Scholar
- Karterud, S., Pedersen, G., Friis, S., Urnes, 0., Irion, T., Brabrand, J., Falkum, L.R., and LeirvAg, H., 1998, The Norwegian Network of psychotherapeutic day hospitals. Ther. Comm. 19: 15–28.Google Scholar
- Nordern, M.J., 1989, Fluoxetine in borderline personality disorder, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 13: 885–893.Google Scholar
- Piper, W.E., Joyce, A.S., Rosie, J.S., and Azim, H FA,1994, Psychological mindedness, work and outcome in day treatment, Int. J. Group Psychotherapy 44: 291–311.Google Scholar
- Rosenberg, R., 1994, Borderline states: pharmacotherapy and psychobiology of personality. A discussion of Soloff’s article, Acta Psychiatr. Scand. 89 (Suppl. 379): 56–60.Google Scholar
- Salzman, C., Wolfson, A.N., Schatsberg, A., Looper, J., Henke, R., Albanese, M., Schwartz, J., and Miyawaki, E., 1995, Effect of fiuoxetine on anger in symptomatic volunteers with borderline personality disorder, J. Clin. Pharmacol. 15: 23–29.Google Scholar
- Sato, T., Sakado, K., and Sato, S., 1993, Is there any specific personality disorder or personality disorder cluster that worsens the short-term treatment outcome of major depression? Acta Psychiatr. Scand. 88: 342–349.Google Scholar
- Soloff, P.H., 1994, Is there any drug treatment of choice for the borderline patient? Acta Psychiatr. Scand. 89 (Suppl. 379): 50–55.Google Scholar